Amylyx Pharmaceuticals, Inc.
AMLX
$32.40
-$1.48-4.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.18% | -25.11% | 4.03% | 17.03% | -15.42% |
| Total Depreciation and Amortization | -56.12% | -9.26% | -10.00% | -14.89% | -9.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -25.43% | 95.34% | -16.06% | -4.24% | 18.73% |
| Change in Net Operating Assets | 191.71% | -5,817.39% | 104.75% | -119.42% | 208.26% |
| Cash from Operations | 14.80% | -32.18% | 8.12% | -20.28% | 36.60% |
| Capital Expenditure | -- | -- | -258.33% | -41.18% | -54.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -513.01% | 22.70% | 461.86% | -77.14% | 152.72% |
| Cash from Investing | -513.10% | 23.06% | 462.80% | -77.23% | 152.67% |
| Total Debt Issued | -- | -- | -100.20% | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.44% | 1,803.99% | -85.86% | 3,593.06% | -92.58% |
| Repurchase of Common Stock | 87.47% | -1,786.12% | 90.34% | -2,000.97% | 88.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.03% | 1,646.63% | -100.11% | 618,183.87% | -100.05% |
| Foreign Exchange rate Adjustments | 38.74% | -194.07% | -21.85% | -75.16% | 208.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7,332.90% | 68.54% | -99.11% | 10,035.90% | 90.48% |